CARMAT : 21 février 2024 : le registre ELEVATE vous invite…

Systole

07 septembre 2024 •11:03

https://pubmed.ncbi.nlm.nih.gov/38036414/

imedtech

09 septembre 2024 •13:36

On peut en effet penser que 63.3% de survie agrave; 5 ans pour une population de patients dont l'age moyen est de 56 ans laisse des posibiliités de faire mieux pour Carmat qui cependant n'a pas le recul qui permette de conclure.
"Results: Primary implant cohort patients had a mean age of 56 years and were predominantly male (89%) with 48% ischaemic aetiology. The majority of subjects was designated bridge to transplant (66%) and had INTERMACS Profiles 1-3 (70%). At baseline, the subjects had poor functional capacity (104 ± 140 m) and impaired QoL (35 ± 19 points). The overall survival rate of the PIC was 63.3% and survival free of stroke was 58.1% at 5 years. Significant improvements in functional capacity and QoL were observed and maintained for 5 years (301 ± 131 m and 64 ± 20 points, respectively).

Conclusions: Real-world data from the ELEVATE registry demonstrate an overall survival rate for primary implants of 63.3%. In the PIC, reductions in adverse events for patients in the extended follow-up and improved QoL and functional capacity were observed at 5 years in this patient population with advanced heart failure."

imedtech

09 septembre 2024 •22:30

Correction : 63.3% de survie a 5 ans

Bingo007

10 septembre 2024 •14:45

Le doc universel sur le site carmat donne aussi des pourcentages comparatifs.